© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep
Based on recent data, Unicycive Therapeutics, Inc. (UNCY) shows an Average True Range (ATR) of 0.37 and an Enterprise Value of 27.26M. Its average trading volume over the past 3 months is 410.64K, indicating liquidity. These fundamental metrics provide insight into UNCY's underlying financial health and market activity.
Unicycive Therapeutics, Inc. (UNCY) technical indicators as of January 1, 2026: the SMA 20 is -4%, SMA 50 at 4.41%, and SMA 200 at 8.16%. The RSI 14 value is 49.58, suggesting its current momentum. These technical analysis signals help assess UNCY's price trends and potential future movements.
Unicycive Therapeutics, Inc. (UNCY) stock performance overview as of January 1, 2026: The 52-week high is $11 (currently -47.55% below), and the 52-week low is $3.71 (currently 55.53% above). Over the past year, UNCY's performance is -13.91%, compared to the S&P 500's 12.29% change.
According to market data, Unicycive Therapeutics, Inc. (UNCY) stock's recent performance metrics show that over the last month, UNCY is -10.82%, with a Year-to-Date (YTD) performance of -27.35%. Over the past year, the stock has seen a -13.91% change. These figures summarize UNCY's price movements across various periods, reflecting its historical returns.
According to current financial data, UNCY stock's P/E (TTM) ratio is -3.11, which compares to the S&P 500's P/E of 32.59. The sector median P/E is -1.24. Key valuation ratios for UNCY, including P/S (N/A), P/B (2.77), and P/FCF (-3.40), offer insights into how the company is valued relative to its earnings, sales, book value, and free cash flow.